Annals of Surgical Oncology

, 15:2310 | Cite as

Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer

  • Philipp Wagner
  • Moritz Koch
  • Daniel Nummer
  • Sylvia Palm
  • Luis Galindo
  • Daniel Autenrieth
  • Friedrich H. Schmitz-Winnenthal
  • Volker Schirrmacher
  • Markus W. Büchler
  • Philipp Beckhove
  • Jürgen Weitz
Laboratory Research

Abstract

Background

Tumor-infiltrating T lymphocytes (TIL) play an important role in primary colorectal cancer, but their activity in liver metastases has not yet been investigated. The aim of this study was to examine whether tumor-selective infiltration, activation, and cytotoxic activity of TIL can be demonstrated in situ in colorectal liver metastases.

Methods

TIL were obtained from liver metastases and corresponding normal liver tissue of 16 patients with colorectal liver metastases. Characterization of TIL in situ was performed by multicolor flowcytometric analysis. Presence of tumor antigen-reactive T cells was evaluated by interferon gamma Elispot analysis.

Results

TIL in colorectal liver metastases responding against tumor antigens were present in most patients. Although the proportions of CD3+ T cells were comparable in liver metastasis and normal liver tissue, metastases contained significantly enhanced proportions of CD4+ cells (49% vs. 22%, P < .001). Among all CD4+ T helper cells, the proportion of activated (CD4+CD25+) effector cells was significantly increased in liver metastases (15.0% vs. 7.8%, P = .003). Metastases showed significantly higher proportions of activated (CD69+ [70.1% vs. 49.8%, P = .02] and CD25+ [4.1% vs. .6%, P = .06]) and cytotoxically active (CD107a+) CD8+ TIL (3.2% vs. 1.3%, P = .03). Importantly, the presence of activated T helper cells correlated with the frequencies of cytotoxic T lymphocytes that exerted cytotoxic activity in situ (P = .02).

Conclusion

CD4+ and CD8+ TIL are selectively activated in liver metastases, and cytotoxic T lymphocytes exert tumor-selective cytotoxic activity in situ in the presence of activated T helper cells, suggesting the requirement of in-situ-activated T helper cells for efficient cytotoxic T lymphocytes effector function.

Keywords

Liver metastasis Colorectal cancer Tumor-infiltrating lymphocytes Anti-tumor immune response Regulatory T cells 

References

  1. 1.
    Weitz J, Koch M, Debus J, et al. Seminar: colorectal cancer. Lancet 2005;365:153–65PubMedCrossRefGoogle Scholar
  2. 2.
    Mocellin S, Mandruzzato S, Bronte V, et al. Vaccines for solid tumours. Lancet Oncol 2004;5:681–9PubMedCrossRefGoogle Scholar
  3. 3.
    Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004;92:13–27PubMedCrossRefGoogle Scholar
  4. 4.
    Parmiani G. Tumor-infiltrating T cells—friend or foe of neoplastic cells? N Engl J Med 2005;353:2640–1PubMedCrossRefGoogle Scholar
  5. 5.
    Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711–7PubMedGoogle Scholar
  6. 6.
    Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;61:3491–4Google Scholar
  7. 7.
    Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493–501PubMedCrossRefGoogle Scholar
  8. 8.
    Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4PubMedCrossRefGoogle Scholar
  9. 9.
    Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004;91:469–75PubMedCrossRefGoogle Scholar
  10. 10.
    Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654–66PubMedCrossRefGoogle Scholar
  11. 11.
    Koch M, Beckhove P, Op dW, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006;244:986–92PubMedCrossRefGoogle Scholar
  12. 12.
    Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994;12:456–65PubMedCrossRefGoogle Scholar
  13. 13.
    Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T-cells. Nat Med 2003;9:1377–82PubMedCrossRefGoogle Scholar
  14. 14.
    Bai L, Beckhove P, Feuerer M, et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 2003;103:73–83PubMedCrossRefGoogle Scholar
  15. 15.
    Solomayer EF, Feuerer M, Bai L, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 2003;9:174–80PubMedGoogle Scholar
  16. 16.
    Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452–8PubMedCrossRefGoogle Scholar
  17. 17.
    Schmitz-Winnenthal FHVC, Zgraggen K, Galindo L, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65:10079–87PubMedCrossRefGoogle Scholar
  18. 18.
    Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006;177:896–904PubMedGoogle Scholar
  19. 19.
    Diederichsen ACP, Hjelmborg JvB, Christensen PB, et al. Prognostic value of the CD4+/CD8* ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immun 2003;52:423–8Google Scholar
  20. 20.
    Nummer D, Suri-Payer E, Schmitz-Winnenthal H, et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007;99:1188–99PubMedCrossRefGoogle Scholar
  21. 21.
    Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 2006;16:73–9PubMedCrossRefGoogle Scholar
  22. 22.
    Koizumi K, Hojo S, Akashi T, et al. Chemokine receptors in cancer metastasis and cancer cell–derived chemokines in host immune response. Cancer Sci 2007;98:1652–8PubMedCrossRefGoogle Scholar
  23. 23.
    Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67:4725–31PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Philipp Wagner
    • 1
  • Moritz Koch
    • 1
  • Daniel Nummer
    • 2
  • Sylvia Palm
    • 1
  • Luis Galindo
    • 1
  • Daniel Autenrieth
    • 1
  • Friedrich H. Schmitz-Winnenthal
    • 1
  • Volker Schirrmacher
    • 2
  • Markus W. Büchler
    • 1
  • Philipp Beckhove
    • 2
  • Jürgen Weitz
    • 1
  1. 1.Department of SurgeryUniversity of HeidelbergHeidelbergGermany
  2. 2.Division of Cellular Immunology, Tumor Immunology ProgramGerman Cancer Research CenterHeidelbergGermany

Personalised recommendations